Eli Lilly formally joined rival Novo Nordisk inside the Hims & Hers platform on Friday, announcing a commercial partnership that lets patients consult a licensed provider, receive a prescription, and have one of two FDA-approved weight-loss drugs shipped directly to their door — all without leaving the Hims & Hers app. The deal covers Zepbound (tirzepatide), Lilly’s blockbuster weekly injectable at $299 per month, and Foundayo (orforglipron), the company’s newer once-daily oral pill at $149 per month. Both match the existing self-pay prices at Lilly’s own direct-to-consumer channel, LillyDirect.

For patients who pay out of pocket — a large and growing segment of the GLP-1 market, since most commercial insurers still do not cover obesity drugs — the practical effect is straightforward: they no longer need to exit the Hims & Hers app to reach Lilly’s medicines.

From Informal Routing to Full Integration

The formal partnership closes a chapter that began informally in April 2026, when Hims & Hers announced that licensed providers on its platform could send prescriptions for Zepbound and Foundayo to the LillyDirect pharmacy. That arrangement came with an explicit disclaimer: Hims & Hers described itself as unaffiliated with Lilly, and the routing was a workaround rather than a commercial agreement.

What changed Friday is both structural and contractual. The prescription-to-doorstep pathway is now embedded inside Hims & Hers’ own platform rather than handed off to LillyDirect. The two companies have made binding commitments, the most significant of which is that Hims & Hers will not offer compounded versions of either drug, now or in the future. According to the joint announcement, the platform has never sold compounded copies of Lilly’s medicines — a key distinction from its prior arrangement with Novo Nordisk, where the March 2026 settlement explicitly required Hims to wind down an active compounded semaglutide business.

Hims & Hers weight-loss membership bundles more than a prescription: it includes around-the-clock access to a clinical care team, nutrition guidance, regular check-ins, and an online weight-loss community.

“Millions of people turn to Hims & Hers for their care,” said Ilya Yuffa, executive vice president and president of Lilly USA and Global Customer Capabilities, “and through this agreement, those patients now have a simple, more direct way to get FDA-approved Lilly medicine at an affordable price if prescribed.”

Andrew Dudum, Hims & Hers’ co-founder and CEO, described the arrangement as deepening the company’s work with Lilly to make “proven, effective GLP-1 therapies more accessible” through medically supervised care in a single platform.

Two Products, Two Different Competitive Challenges

The two drugs Lilly is pushing through this channel have distinct profiles — and face different competitive pressures.

Zepbound (tirzepatide) is a once-weekly injectable that posted $5.35 billion in Q3 2026 global sales, up 49% year-over-year, making it the fastest-growing branded drug in the obesity market. It is the first medication FDA-approved for both weight management and moderate-to-severe obstructive sleep apnea in adults with obesity — a secondary indication that broadens its addressable population. In Lilly’s pivotal SURMOUNT trials, the highest dose (15 mg) produced up to 20.9% body weight loss at 72 weeks; the drug is unique in activating both the GLP-1 and GIP receptors simultaneously, which appears to account for its superior results compared with semaglutide in a head-to-head trial.

Tirzepatide is a modified 39-amino-acid peptide delivered by injection because — like all peptide-based GLP-1 drugs — it would be broken down by stomach enzymes if swallowed. That is not a limitation unique to Zepbound; it is a property of the molecule class.

Foundayo (orforglipron) is where the more interesting technology story lives. Approved by the FDA on April 1, 2026 — through the FDA’s newly launched Commissioner’s National Priority Voucher (CNPV) pilot program, completing review in a record 50 days — Foundayo is the first oral weight-loss drug in the GLP-1 class that can be taken at any time of day, with or without food and water. That distinction is not marketing language; it reflects a fundamental difference in molecular architecture.

Why Foundayo has no food restrictions: Most GLP-1 drugs are peptides — modified proteins that stomach acid and digestive enzymes would degrade before they could be absorbed. That is why they require injection. Novo Nordisk’s oral Wegovy (semaglutide) solved the injection problem by co-formulating the peptide with a compound called SNAC — sodium N-[8-(2-hydroxybenzoyl)aminocaprylate] — which temporarily alters the gastric environment to allow peptide absorption across the stomach lining. But SNAC only works reliably in an empty, low-pH stomach with minimal fluid; that is why oral Wegovy requires a 30-minute pre-meal fasting window and a small-sip-of-water restriction.

Orforglipron is a different kind of molecule entirely. It is a small-molecule non-peptide GLP-1 receptor agonist — a synthetic organic compound, not a protein, that activates the GLP-1 receptor without being structurally related to the GLP-1 hormone. Because it is not a peptide, it is not degraded by the same digestive mechanisms. It is absorbed like any conventional oral drug: take it whenever, with whatever. No SNAC required. No timing window. No water restriction.

That architecture comes with trade-offs. Orforglipron is a partial agonist at the GLP-1 receptor — it triggers a submaximal response — which may explain why its weight-loss results are more modest than Zepbound’s. In the pivotal ATTAIN-1 trial, patients on the highest dose who remained on treatment lost an average of 27.3 pounds (12.4% of body weight) at 72 weeks, compared with 2.2 pounds (0.9%) on placebo. Across all participants regardless of adherence, average weight loss was 25 pounds, versus 5.3 pounds on placebo. The most common side effects were gastrointestinal — nausea, diarrhea, and constipation — consistent with the broader GLP-1 class.

Foundayo was originally discovered by Chugai Pharmaceutical and exclusively licensed to Lilly in 2018. It generated $184 million in Q3 2026 in revenue — up from $98 million in the prior quarter, but trailing Novo Nordisk’s oral Wegovy pill, which the company separately launched. The Hims & Hers deal is, in part, Lilly’s answer to that gap.

Lilly Follows Novo — and Closes the Platform

The move puts Lilly on the same commercial footing as Novo Nordisk at Hims & Hers, which reached its own deal in March 2026 after a contentious period that included a patent infringement lawsuit Novo filed against the telehealth company for selling compounded semaglutide. That deal, announced March 9, resolved the litigation: Hims & Hers agreed to stop advertising compounded GLP-1s and transition existing patients to branded medications when providers deemed it clinically appropriate. HIMS shares surged 37–46% on settlement news — a reaction that reflected the market’s read that Hims had survived the IP conflict and secured a supply of the most prescribed weight-loss drug in the world.

Lilly is not Hims & Hers’ first pharma partnership for Zepbound distribution. Ro, another telehealth platform, integrated with LillyDirect for Zepbound delivery in December 2024, offering single-dose vials at $399 per month. Friday’s Hims deal goes further: rather than routing to an external LillyDirect fulfillment step, the entire clinical and fulfillment journey runs inside the Hims & Hers platform. Amazon Pharmacy also participates in the broader LillyDirect distribution network.

For Hims & Hers, the succession of deals with both Lilly and Novo Nordisk signals a completed strategic pivot. The platform has exited the compounded GLP-1 business across the board — first for semaglutide, now formally for tirzepatide and orforglipron as well.

What This Costs Without Insurance — and Why That Matters

A key structural context: GLP-1 obesity drugs remain largely uninsured for most American patients. Medicare only began offering access to Zepbound and Foundayo at reduced rates under the Medicare GLP-1 Bridge program in mid-2026; commercial insurance coverage has been contracting. Without insurance or a subsidized program, branded GLP-1 drugs can exceed $10,000 per year at standard pharmacy prices.

Hims & Hers’ pricing — $1,788 per year for Foundayo and $3,588 per year for Zepbound — represents a reduction of 65 to 82 percent against list price, though still a significant cash commitment for most households. The GLP-1 telehealth platform market itself was valued at approximately $763.8 million in 2026 and is projected to reach $3.28 billion by 2036, with direct-to-consumer cash-pay subscriptions as the dominant revenue model.

Lilly’s decision to integrate directly into Hims & Hers — rather than simply continuing to redirect customers to LillyDirect — is a commercial recognition that the friction of platform-switching is itself a barrier to access.

What Changes for Patients Today

Patients who use Hims & Hers for weight management and pay out of pocket can, beginning today:

• Access Foundayo ($149/month) or Zepbound ($299/month) through a single consultation, prescription, and delivery workflow without leaving the app
• Compare Foundayo’s oral, food-unrestricted dosing against Zepbound’s weekly injectable on the same clinical platform
• Access Novo Nordisk’s branded Wegovy and Ozempic (available through the same platform since the March 2026 Novo deal) alongside Lilly’s offerings
• No longer access compounded versions of Lilly’s drugs through Hims & Hers — that pathway is now contractually foreclosed

What changed Friday is not the drugs themselves or their prices. What changed is that the most significant self-pay GLP-1 platform in the country now carries the branded versions of everything the two largest GLP-1 manufacturers make — and has committed not to substitute compounded copies of any of them.